Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 11,500.00
Ask: 12,200.00
Change: 0.00 (0.00%)
Spread: 700.00 (6.087%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE enjoys best day since July; mid-caps gain for 4th week

Fri, 22nd Nov 2019 10:09

* FTSE 100 up 1.2%, FTSE 250 up 0.6%

* Indexes bounce back after 2 days of losses

* Pound falls after PMI data, aids exporters

* Mid-cap Hochschild Mining, Coats Group underperform
(Adds news items, updates to closing prices)

By Shashwat Awasthi and Yadarisa Shabong

Nov 22 (Reuters) - London's FTSE 100 surged more than 1% on
Friday after two days of selling, as investors turned cautiously
optimistic about a Sino-U.S. trade deal and exporter stocks rose
after the pound weakened on downbeat U.K. Purchasing Managers'
Indexes (PMI) data.

The main index was powered on its best day since
late July by trade-sensitive scrips including HSBC and
miners and further bolstered by
internationally-exposed firms such as Unilever and
Diageo.

The FTSE 250 added 0.6%, though gains were capped by
data that showed British business this month suffered its
deepest downturn since mid-2016 amid uncertainty around the
general election and Brexit.

Further keeping gains in check was a 9% slide in Hochschild
Mining after its 2020 output targets disappointed, and
an 8% drop in thread manufacturer Coats Group after it
warned on annual profit.

Hochschild shares endured their worst day since Aug. 2017,
while Coats' shares hit their lowest level in two-and-a-half
years.

Despite this, the mid-caps enjoyed their fourth straight
week of gains, buoyed in recent sessions by polls that point to
a likely Conservative Party victory in the Dec. 12 election.

A Conservative victory is seen as more likely to see through
Brexit and it was this view that led the FTSE 250 to a more than
one-year high earlier this week.

The blue-chip bourse recouped all losses from the past two
sessions as mild risk appetite returned after a report http://bit.ly/2O6RSOl
that Washington may delay tariffs on Chinese imports even if a
deal is not signed by a Dec. 15 deadline.

Furthermore, comments by President Xi Jinping that Beijing
wanted to work out an initial trade pact with Washington and a
softer pound helped the FTSE handily outperform the broader
European benchmark.

"Investors are mindful of the trade deal's importance in
supporting hopes of a global economic recovery next year," FXTM
analyst Han Tan said. "A further escalation in trade tensions
would only undermine the world economy's growth momentum while
amplifying chatter about a recession."

Trade tensions had flared earlier this week after President
Donald Trump threatened to raise tariffs on Chinese imports if
no deal was struck, and after the U.S. Senate backed a bill
supporting protesters in Hong Kong, which drew Beijing's ire.

Shares in AstraZeneca advanced as much as 2.8% after
the drugmaker won earlier-than-expected U.S. regulatory approval
for a leukaemia drug.
(Reporting by Yadarisa Shabong and Shashwat Awasthi in
Bengaluru;
Editing by Subhranshu Sahu, Uttaresh.V and Andrew Cawthorne)

More News
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.